Over the course of 3–5 years, selenium supplementation of 200 or 400 μg did not affect PSA velocity or risk of PCa mortality in high-risk patients (n = 699) in a Phase III randomized, double-blinded placebo-controlled, multi-center trial.85 The gene discussed is KLK3; the disease is posterior cortical atrophy.